SYSTEM U3 FOR CIPROFLOXACIN

K981639 · Ab Biodisk · JWY · Sep 3, 1998 · Microbiology

Device Facts

• Record ID: K981639
• Device Name: SYSTEM U3 FOR CIPROFLOXACIN
• Applicant: Ab Biodisk
• Product Code: JWY · Microbiology
• Decision Date: Sep 3, 1998
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.1640
• Device Class: Class 2

Intended Use

For in vitro diagnostic use: System U3™ is a qualitative technique for antimicrobial susceptibility testing of nonfastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Enterococcus species. The system comprises an antibiotic gradient with MIC break-point concentrations and is used to determine the susceptibility categories of microorganisms to different antimicrobial agents, as tested on agar media using overnight incubation. This 510(k) application is for System U3/Ciprofloxacin susceptibility testing based on the MIC breakpoints of Susceptible ≤ 1 ug/ml, Intermediate 2 ug/ml and Resistant ≥ 4 µg/ml for use with non-fastidious Gram negative and Gram positive aerobic bacteria.

Device Story

System U3™ is an in vitro diagnostic device for antimicrobial susceptibility testing. It utilizes an antibiotic gradient strip containing specific concentrations of Ciprofloxacin placed on agar media inoculated with bacterial samples. Following overnight incubation, the device allows for the determination of Minimum Inhibitory Concentration (MIC) values. The system categorizes microorganisms as Susceptible (≤ 1 µg/ml), Intermediate (2 µg/ml), or Resistant (≥ 4 µg/ml). Used in clinical laboratories by trained personnel; results assist clinicians in selecting appropriate antibiotic therapy for patients with bacterial infections.

Clinical Evidence

No clinical data provided. Substantial equivalence is based on bench testing of the antibiotic gradient system and performance against established MIC breakpoints for Ciprofloxacin.

Technological Characteristics

Antibiotic gradient strip for agar-based susceptibility testing. Determines MIC via concentration gradient. Manual interpretation of growth inhibition zones/MIC values. In vitro diagnostic use.

Indications for Use

Indicated for in vitro diagnostic antimicrobial susceptibility testing of non-fastidious Gram-negative and Gram-positive aerobic bacteria (e.g., Enterobacteriaceae, Pseudomonas, Staphylococcus, Enterococcus).

Regulatory Classification

Identification

An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.

Submission Summary (Full Text)

{0}------------------------------------------------

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

## SEP 3 1998

Anne Bolmstrom President AB BIODISK Dalvagen 10 S-169 56 Solna Sweden

Re: K981639

> Trade Name: System U3™ for Ciprofloxacin Regulatory Class: II Product Code: JWY Dated: July 1, 1998 Received: July 8, 1998 ----

Dear Ms. Bolmstrom:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{1}------------------------------------------------

## Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number [phone] or at [phone] or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Enclosure 2

Page 1 of 1

510(k) Number (if known):

Device Name: System U3™ for Ciprofloxacin

Indications For Use:

For in vitro diagnostic use:

System U3™ is a qualitative technique for antimicrobial susceptibility testing of nonfastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Enterococcus species. The system comprises an antibiotic gradient with MIC break-point concentrations and is used to determine the susceptibility categories of microorganisms to different antimicrobial agents, as tested on agar media using overnight incubation.

This 510(k) application is for System U3/Ciprofloxacin susceptibility testing based on the MIC breakpoints of Susceptible ≤ 1 ug/ml, Intermediate 2 ug/ml and Resistant ≥ 4 µg/ml for use with non-fastidious Gram negative and Gram positive aerobic bacteria.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

| | Wordey Dubois |
|-----------------------------------------|---------------|
| (Division Sign Off) | |
| Division of Clinical Laboratory Devices | |
| 510(k) Number | K981639 |

Prescription Use (Per 21 CFR 801.10

OR

Over-The Counter Use

(Optional Format 1-2-96)